Cadrenal Therapeutics, Inc. Cost of Revenue
Cadrenal Therapeutics, Inc. (CVKD) reported Cost of Revenue of $220.09 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-11.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2024-03-11
- Cadrenal Therapeutics, Inc. cost of goods and services sold for the quarter ending 2023-12-31 was $0.00.
- Cadrenal Therapeutics, Inc. cost of goods and services sold for the quarter ending 2023-09-30 was $0.00.
- Cadrenal Therapeutics, Inc. cost of goods and services sold for fiscal 2023 was $220.09K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-11 | $220.09K 10-K · filed 2024-03-11 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $220.09K 10-Q · filed 2023-11-09 | ||
| 2023-06-30 | $220.09K 10-Q · filed 2023-08-10 | |||
| 2008-03-31 | $220.09K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B |